查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1609174

下一代婦科癌症診斷市場：按組件、技術、適應症和最終用戶分類 - 全球預測 2025-2030

Next-Generation Gynecological Cancer Diagnostics Market by Components (Consumables, Instruments, Software), Technology (Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR)), Indication, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

下一代婦科癌症診斷市場2023年估值為21.3億美元，預計2024年將達到23.2億美元，複合年成長率為10.49%，到2030年將達到42億美元，預計將達到9000萬美元。

下一代婦科癌症診斷市場包括在早期、可治療階段檢測子宮頸癌、卵巢癌和子宮內膜癌等癌症的先進技術和方法。在癌症發生率上升、意識增強以及個人化醫療需求的推動下，這些診斷方法被證明比傳統方法更準確和有效，最終改善患者的治療效果極為重要。應用範圍涵蓋篩檢、診斷和監測，主要最終用戶包括醫院、診斷實驗室和研究機構。市場勢頭受到分子診斷技術進步、用於資料分析的人工智慧 (AI) 整合以及促進產品快速開發和核准的支援性監管環境的顯著影響。擴大就地檢驗和加強液態切片技術存在機會，特別是在醫療基礎設施有限的服務開拓地區。然而，該市場面臨挑戰，例如先進診斷工具的成本高昂、缺乏適當的報銷政策以及阻礙開發中國家認知和獲取的社會文化障礙。儘管存在這些障礙，創新和研究應專注於開發具有成本效益的解決方案，提高靈敏度和特異性，並推進可實現遠距離診斷的遠端醫療平台。利用次世代定序儀（NGS）、生物標記發現和人工智慧應用的平台對於市場進入者來說尤其有前景。與醫療保健提供者的策略聯盟以及與學術機構的合作將加速創新，而對數位醫療的日益接受將進一步刺激市場擴張。調整衛生政策和增加研發投資可能會緩解現有的限制，但要抓住市場潛力，積極適應技術進步並解決全球醫療保健取得方面的差異至關重要。市場仍然充滿活力，公司需要保持敏捷和前瞻性的方法，以開發下一代婦科診斷技術的巨大潛力。

主要市場統計
基準年[2023] 21.3億美元
預計年份 [2024] 23.2億美元
預測年份 [2030] 42.9億美元
複合年成長率（%） 10.49%

市場動態：揭示快速發展的下一代婦科癌症診斷市場的關鍵市場洞察

供需的動態交互作用正在改變下一代婦科癌症診斷市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 下一代婦科癌症患者增加
    • 傾向於疾病的早期診斷和治療
    • 利用新的遺傳標記
  • 市場限制因素
    • 下一代婦科癌症診斷相關的高成本
  • 市場機會
    • 遠端醫療和遠端監控新趨勢
    • 增加篩檢項目和醫療旅遊
  • 市場問題
    • 製造下一代婦科癌症診斷測試​​的複雜性

波特五力：引領下一代婦科癌症診斷市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解下一代婦科癌症診斷市場的外部影響

外部宏觀環境因素在塑造下一代婦科癌症診斷市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解下一代婦科癌症診斷市場的競爭格局

下一代婦科癌症診斷市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：下一代婦科癌症診斷市場供應商的績效評估

FPNV 定位矩陣是評估下一代婦科癌症診斷市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製下一代婦科癌症診斷市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對下一代婦科癌症診斷市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、主要產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 下一代婦科癌症發生率上升
      • 疾病的早​​期診斷和治療趨勢
      • 利用新的遺傳標記
    • 抑制因素
      • 下一代婦科癌症診斷相關的高成本
    • 機會
      • 遠端醫療和遠端監控新趨勢
      • 增加檢測項目和醫療旅遊
    • 任務
      • 製造下一代婦科癌症診斷測試​​的複雜性
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章下一代婦科癌症診斷市場：按組成部分

  • 介紹
  • 消耗品
  • 裝置
  • 軟體

第7章下一代婦科癌症診斷市場：透過技術

  • 介紹
  • 次世代定序（NGS）
  • 聚合酵素鏈鎖反應(PCR)

第8章下一代婦科癌症診斷市場：依適應症分類

  • 介紹
  • 子宮頸癌
  • 卵巢癌
  • 子宮癌

第9章下一代婦科癌症診斷市場：依最終用戶分類

  • 介紹
  • 學術研究所
  • 診斷實驗室
  • 醫院及門診中心

第10章北美和南美下一代婦科癌症診斷市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太下一代婦科癌症診斷市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的下一代婦科癌症診斷市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • ARUP Laboratories
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Fulgent Genetics, Inc.
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Interpace Diagnostics, LLC
  • Janssen Pharmaceuticals, Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • Lucence Diagnostics Pte Ltd
  • Medtronic plc
  • Merck KGaA
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Novartis AG
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF1

The Next-Generation Gynecological Cancer Diagnostics Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.32 billion in 2024, and is projected to grow at a CAGR of 10.49%, to USD 4.29 billion by 2030.

The next-generation gynecological cancer diagnostics market encompasses advanced technologies and methods for detecting cancers such as cervical, ovarian, and endometrial at earlier and more treatable stages. With increased necessity driven by rising cancer prevalence, heightened awareness, and demand for personalized medicine, these diagnostics are pivotal in offering improved accuracy and efficiency over traditional methods, ultimately enhancing patient outcomes. Applications span screening, diagnostics, and monitoring, with major end-users including hospitals, diagnostic labs, and research institutions. The market's momentum is significantly influenced by technological advancements in molecular diagnostics, the integration of artificial intelligence (AI) for data analysis, and supportive regulatory landscapes, fostering expedited product development and approvals. Opportunities lie in expanding point-of-care testing and enhancing liquid biopsy techniques, particularly in underserved regions with limited access to healthcare infrastructure. However, the market faces challenges such as high costs of advanced diagnostic tools, a lack of adequate reimbursement policies, and socio-cultural barriers hindering awareness and accessibility in developing countries. Despite these obstacles, innovation and research should focus on cost-effective solution development, increasing sensitivity and specificity, and advancing telehealth platforms to enable remote diagnostics. Platforms leveraging next-gen sequencing (NGS), biomarker discovery, and AI applications are particularly promising for market entrants. Strategic partnerships with healthcare providers and academic collaborations can accelerate innovation, with the growing acceptance of digital health further stimulating market expansion. While healthcare policy adjustments and increased investment in R&D could mitigate existing limitations, capturing market potential requires proactive adaptation to technological advancements and addressing disparities in healthcare access globally. The market remains fundamentally dynamic, requiring businesses to remain agile and forward-thinking in their approach to tap into the vast potential of next-generation diagnostic technologies in gynecological healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.32 billion
Forecast Year [2030] USD 4.29 billion
CAGR (%) 10.49%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Gynecological Cancer Diagnostics Market

The Next-Generation Gynecological Cancer Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of next-generation gynecological cancer cases
    • Inclination towards early diagnosis and treatment of diseases
    • Utilization of novel markers and genetic markers
  • Market Restraints
    • High cost associated with next generation gynecological cancer diagnostics
  • Market Opportunities
    • Emerging trend of telemedicine and remote monitoring
    • Growing number of screening programs and medical tourism
  • Market Challenges
    • Complexity in manufacturing of next generation gynecological cancer diagnostics tests

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Gynecological Cancer Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Gynecological Cancer Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Gynecological Cancer Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Gynecological Cancer Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Gynecological Cancer Diagnostics Market

A detailed market share analysis in the Next-Generation Gynecological Cancer Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Gynecological Cancer Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Gynecological Cancer Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Gynecological Cancer Diagnostics Market

A strategic analysis of the Next-Generation Gynecological Cancer Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Gynecological Cancer Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Becton, Dickinson and Company, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, Fulgent Genetics, Inc., GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Interpace Diagnostics, LLC, Janssen Pharmaceuticals, Inc., Konica Minolta, Inc., Koninklijke Philips N.V., Lucence Diagnostics Pte Ltd, Medtronic plc, Merck KGaA, Myriad Genetics, Inc., Natera, Inc., Novartis AG, QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Gynecological Cancer Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Components, market is studied across Consumables, Instruments, and Software.
  • Based on Technology, market is studied across Next-Generation Sequencing (NGS) and Polymerase Chain Reaction (PCR).
  • Based on Indication, market is studied across Cervical Cancer, Ovarian Cancer, and Uterine Cancer.
  • Based on End User, market is studied across Academic & Research Institutes, Diagnostic Laboratories, and Hospitals & Ambulatory Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of next-generation gynecological cancer cases
      • 5.1.1.2. Inclination towards early diagnosis and treatment of diseases
      • 5.1.1.3. Utilization of novel markers and genetic markers
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with next generation gynecological cancer diagnostics
    • 5.1.3. Opportunities
      • 5.1.3.1. Emerging trend of telemedicine and remote monitoring
      • 5.1.3.2. Growing number of screening programs and medical tourism
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing of next generation gynecological cancer diagnostics tests
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Next-Generation Gynecological Cancer Diagnostics Market, by Components

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Software

7. Next-Generation Gynecological Cancer Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Next-Generation Sequencing (NGS)
  • 7.3. Polymerase Chain Reaction (PCR)

8. Next-Generation Gynecological Cancer Diagnostics Market, by Indication

  • 8.1. Introduction
  • 8.2. Cervical Cancer
  • 8.3. Ovarian Cancer
  • 8.4. Uterine Cancer

9. Next-Generation Gynecological Cancer Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Diagnostic Laboratories
  • 9.4. Hospitals & Ambulatory Centers

10. Americas Next-Generation Gynecological Cancer Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Next-Generation Gynecological Cancer Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Next-Generation Gynecological Cancer Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agilent Technologies, Inc.
  • 3. ARUP Laboratories
  • 4. Becton, Dickinson and Company
  • 5. BGI Genomics Co., Ltd.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Centogene N.V.
  • 8. Danaher Corporation
  • 9. Epic Sciences Inc.
  • 10. Exact Sciences Corporation
  • 11. F. Hoffmann-La Roche Ltd.
  • 12. Fujifilm Holdings Corporation
  • 13. Fulgent Genetics, Inc.
  • 14. GE HealthCare Technologies, Inc.
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. Interpace Diagnostics, LLC
  • 18. Janssen Pharmaceuticals, Inc.
  • 19. Konica Minolta, Inc.
  • 20. Koninklijke Philips N.V.
  • 21. Lucence Diagnostics Pte Ltd
  • 22. Medtronic plc
  • 23. Merck KGaA
  • 24. Myriad Genetics, Inc.
  • 25. Natera, Inc.
  • 26. Novartis AG
  • 27. QIAGEN N.V.
  • 28. Siemens Healthineers AG
  • 29. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS & AMBULATORY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPONENTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. NEXT-GENERATION GYNECOLOGICAL CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023